The prevalence of LAG3+ BC (defined as >1% CD4+ or CD8+ LAG3+ TIL by FACS) was associated with ERneg, the clinical subtypes TNBC and HER2+, and a presence of TIM3+ or PD-L2+ TIL (Table S10B in Supplementary Material); however, after correcting for multiple testing, these results were not statistically significant, again likely due to sample size. Here, CD4 is linked to breast cancer.